子宫腺肌病患者在腺肌病病灶切除术前行促性腺激素释放激素激动剂预处理的价值
研究纳入87例子宫腺肌病患者,随机分为GnRH-a预处理2-3周期后手术组(41例)和直接手术对照组(46例)。结果显示预处理组在术中出血量、手术时间、引流时间及引流量、血红蛋白下降幅度、术后白细胞计数、围手术期输血比例及住院时间方面均优于对照组(均P<0.05)。结论认为术前GnRH-a预处理有利于手术实施并减少围手术期及术后并发症。
要点
- GnRH-a预处理2-3周期可减少腺肌病病灶切除术中出血量(113±32 ml vs 194±42 ml,P<0.05)。
- 预处理组手术时间、盆腔引流时间及引流量、住院时间均低于对照组(均P<0.05)。
- 预处理组围手术期输血比例为5%(2/41),对照组为20%(9/46),差异有统计学意义(P<0.05)。
核心结论
- 子宫腺肌病患者在腺肌病病灶切除术前行GnRH-a预处理有利于手术实施并减少围手术期及术后并发症。
研究设计与样本
- 2012年5月至2015年9月纳入武汉大学人民医院87例保守治疗无效的子宫腺肌病患者,按随机对照原则分为治疗组41例(术前GnRH-a 2-3周期)和对照组46例(无预处理直接手术)。
主要发现
- 治疗组GnRH-a治疗前后子宫大小、血红蛋白及CA125值差异均有统计学意义(均P<0.05)。
- GnRH-a治疗2周期与3周期比较,血红蛋白为(108±20)vs(118±24)g/L,CA125为(26±11)vs(19±4)kU/L,差异均有统计学意义(均P<0.05)。
- 治疗组与对照组比较:术中出血量(113±32)vs(194±42)ml,手术时间(79±23)vs(91±25)分钟,术后盆腔引流时间(2.1±0.9)vs(3.0±1.2)天,引流量(152±43)vs(232±32)ml,术前术后血红蛋白差值(-15.6±2.9)vs(-23.7±3.5)g/L,术后2-3天白细胞计数(11.4±4.2)×10⁹/L vs(13.5±3.2)×10⁹/L,围手术期输血比例5%(2/41)vs 20%(9/46),住院时间(11.2±1.9)vs(13.6±3.1)天,差异均有统计学意义(均P<0.05)。
- 治疗组与对照组穿透子宫腔比例分别为12%(5/41)与12%(8/46),差异有统计学意义(P<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the value of using gonadotropin-releasing hormone agonist (GnRH-a) pretreatment in adenomyosis patients before adenomyomectomy. Methods: From May 2012 to September 2015, 87 patients with adenomyosis who were non-effective to conservative therapy in Renmin Hospital of Wuhan University were enrolled in this study. According to the principle of randomized control, 41 patients were in the treatment group who were treated with GnRH-a 2-3 cycles before adenomyomectomy, while 46 patients in the control group. The control group paients were operated without any pretreatments. The blood loss, the number of penetrating into uterine cavity, duration of operation, duation of peritoneal drainage and the amount of drainage fluid, the difference of hemoglobin value before and after operation, total white blood cell count, duration of hospitalization, the maximum diameter of uterus and other indicators between the two groups were compared. Results: In the treatment group, before and after treatment with GnRH-a, the uterus size, blood hemoglobinand CA125 value were statistically different (all P<0.05); between the treatment group of GnRH-a treated for 2 cycles and for 3 cycles, there were statistical differences of blood hemoglobin value [(108 ± 20) versus (118 ± 24) g/L], CA125 value [(26 ± 11) versus(19 ± 4) kU/L; all P< 0.05]. There were statistical differences of blood loss in operation [(113 ± 32) versus (194 ± 42) ml], ratio of penetrating into uterine cavity [12% (5/41) versus 12% (8/46)], duration of operation[(79±23) versus (91±25) minutes], duration of peritoneal drainage after operation [(2.1±0.9) versus (3.0±1.2) days] and the amount of drainage fluid [(152±43) versus (232±32) ml], the difference of hemoglobin value before and after surgery [(-15.6±2.9) versus (-23.7±3.5) g/L], white blood cell count after 2-3 days of operation [(11.4±4.2)×109/L versus (13.5 ± 3.2) × 109/L], ratio of peri-operative blood transfusion [5% (2/41) versus 20% (9/46)] and duration of hospitalization [(11.2±1.9) versus (13.6±3.1) days] between the treatment group and the control group (all P<0.05). Conclusion: The pretreatment of using GnRH-a before adenomyomectomy in adenomyosis patients has benefits for implementation of surgery and reducing peri-operative and postoperative complications.
引用
- Tan AL, Luo RY, Gong M, et al. [Value of using gonadotropin-releasing hormone agonist pretreatment in adenomyosis patients before adenomyomectomy]. Zhonghua Fu Chan Ke Za Zhi. 2016. PMID: 28057126. doi:10.3760/cma.j.issn.0529-567X.2016.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。